The counter has had a total traded volume of 56595 shares so far with a value of Rs 2.06 crore on the NSE. It traded at a price-to-earnings multiple of 67.93 and a price-to-book ratio of 6.51.
A higher P/E ratio shows investors are willing to pay a higher price for per rupee earnings given by the stock because of better future growth expectations.
The price-to-book value indicates the inherent value of a company and reflects the price investors are willing to pay even for no growth in the business.
The scrip declined 15.88 per cent during the past one year, while the 30-share index advanced 35.5 per cent during the same period.
Biocon Ltd. belongs to the Pharma – Indian industry.
Promotor/FII Holding
Promoters held 39.73 per cent stake in the company as of 30-Sep-2021, while FIIs and domestic institutional investors ownership stood at 15.74 per cent and 2.58 per cent, respectively.
Key Financials
The firm reported consolidated net sales of Rs 1945.3 crore for the quarter ended 30-Sep-2021, up 7.61 per cent from the previous quarter’s Rs 1807.8 crore and up 10.51 per cent from the year-ago quarter’s Rs 1760.3 crore.
Profit for the latest quarter stood at Rs 138.3 crore, down 18.31 per cent from the same quarter a year ago.
